NCT01069094View on ClinicalTrials.gov

A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Uterine Leiomyomata
Interventions
DRUG

Progenta

12.5 mg, administered as a once daily oral dose for 90 days.

DRUG

Progenta

25 mg, administered as a once daily oral dose for 90 days.

DRUG

Progenta

50 mg, administered as a once daily oral dose for 90 days.

DRUG

Lucron Depot

3.75 mg IM monthly

DRUG

Placebo

Administered as a once daily oral dose for 90 days.

Trial Locations (1)

02-106

Medical University /MTZ Clinical Research Sp.zo.o., Warsaw

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01069094 - A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata | Biotech Hunter | Biotech Hunter